SUMMARY The motor and cognitive effects ofa selective D-l dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3-2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. in Huntington's disease and Gilles de la Tourette's syndrome. For example, D-l receptor stimulation appears to modify attentional mechanisms in rats, alter the animals' responses to novel and noxious stimuli, and affect their ability to switch from one behavioural set to another."
The D-2 dopamine receptor has previously been considered most closely related to extrapyramidal motor function. 4 Nevertheless, recent preclinical observations suggest that D-1 receptors may also participate in the generation of involuntary and cognitive deficits that attend certain hyperkinetic disorders.9 Clinical experience also supports the notion that D-1 receptor mediated mechanisms contribute to the production of choreiform movements. Treatment of Parkinson's disease with non-selective D-1/D-2 dopaminomimetics such as levodopa results in doselimiting facial, appendicular and axial dyskinesias. When treatment is initiated with the relatively selective D-2 agonist bromocriptine, the appearance of these movements may be delayed.'0 Studies in the experimental animal also implicate D-1 receptor mechanisms in the behavioural alterations that occur in Huntington's disease and Gilles de la Tourette's syndrome. For example, D-l receptor stimulation appears to modify attentional mechanisms in rats, alter the animals' responses to novel and noxious stimuli, and affect their ability to switch from one behavioural set to another."
In an attempt to evaluate the contribution of D-1 dopamine receptor mediated mechanisms to the motor and cognitive changes associated with hyperkinetic extrapyramidal disease, SKF 38393, a selective D-l receptor agonist2 was administered under doubleblind placebo-controlled design conditions to patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia and torsion dystonia.
Methods
Five patients with Huntington's disease ( Values are the mean of 2 ratings by 2 independent observers evaluated 90 minutes after the third daily dose of placebo or SKF 38393 at three different daily dose levels (3-2 ± 0 3 mg/kg, range 2-6 to 3-8 mg/kg; 6-8 ± 0-4 mg/kg, range 6-0 to 7-7 mg/kg; and 12 4 + 1-0 mg/kg, range 10-1 to 15 1 mg/kg). Choreatic movements were rated on a scale of 0 (absent) to 4 (severe), in each of 10 categories and then summed, the maximum possible score being 40. Table 2 Effect ofSKF38393 on cognitivefunction in Huntington's disease Attentional parameters were tested with digit span,2' and with reaction time, consisting of simple and complex response paradigms (go/nogo response) ; verbal cognitive tests assessed both episodic and semantic aspects of memory, through paired associate learning,23 as well as immediate and delayed recall and verbal fluency;' visuospatial tasks included embedded figures25 street map26 and non-verbal fluency"7 tests.
group 0 5) Mean (SEM) AIMS scores derive from 2 blinded ratings performed after the 2nd (patients 8 & 9) or 3rd (patient 10) daily dose of drug or placebo. Choreatic movements and dystonic postures were scored on a scale of 0 (absent) to 4 (severe) in either 6 body parts (tardive dyskinesia) or 10 body parts (torsion dystonia) and these scores were then summed. SKF 38393 daily dosages were 9 5 mg/kg/day for patient 8, 1 1 mg/kg for patient 9, and 32 mg/kg for patient 10. treatment (11, SEM 0-2; daily dose 9 5 mg/kg) than during either the initial placebo (12, SEM 2 5) or second placebo phases (18, SEM 1-3).
The patient with idiopathic torsion dystonia showed no apparent effect on AIMS scores at either of two doses of SKF 38393 (table 5) .
There were no clinically significant adverse effects associated with SKF 38393 administration in any of the patients.
Discussion
The present results indicated that subacute administration ofthe selective D-1 dopamine receptor agonist, SKF 38393, over a wide range of doses had no clinically significant effect on motor function in two patients with tardive dyskinesia and in one patient with idiopathic torsion dystonia, or on either motor or cognitive function in five patients with Huntington's disease and two with Gilles de la Tourette's syndrome. It is unlikely that this lack of efficacy can be attributed to a failure of the drug to cross the blood brain barrier in pharmacologically significant amounts. Unmetabolised SKF 38393 has been demonstrated in human cerebrospinal fluid following the oral administration of doses comparable to the maximum levels used in this study.'2 Moreover, doses of SKF 38393 given our patients, calculated on a mg/kg body weight basis, approximated those which reproducibly modify motor activity in rats,'3 and which produce CSF drug levels similar to those found in rat brain at the time of maximum behavioural response.'2 Further, a stimulatory effect of SKF 38393, in the dose range used in this study, on prolactin secretion has been observed in humans.'4 Because the D-1 agonist has no direct effect on prolactin secreting cells outside the blood brain barrier, the hormone release appears to be centrally mediated.
The negative response to SKF 38393 reported here may reflect a very limited role for D-1 receptor mediated mechanisms in hyperkinetic extrapyramidal 634 motor disease. Conceivably, the pathophysiology and pharmacotherapy of these disorders may relate largely, if not exclusively, to the D-2 subclass of dopamine receptors.
Considerable preclinical evidence, nevertheless, suggests that D-1 receptor mediated mechanisms may participate in the regulation of motor function. In rodents, concurrent stimulation of both D-1 and D-2 receptors appears necessary for the full expression of the motor and electrophysiological effects of dopamine agonists, and the D-1 receptor appears to regulate the level of response to D-2 receptor stimulation.5 D-1 receptor stimulation is a requirement for the induction of stereotypy, a behaviour which serves as an animal model for abnormal involuntary movements in humans.67 Chronic D-1 receptor stimulation appears to be necessary for the appearance of agonist-induced behavioural supersensitivity, a model for the chronic motor and behavioural effects of long-term dopamine agonist administration in Parkinson's disease. 8 In monkeys chronically exposed to neuroleptics, selective D-1 receptor blockade produces acute dystonic reactions and oral dyskinesias, which closely resemble those seen in patients with extrapyramidal disorders. 9 The inability of SKF 38393 to modify motor function in the extrapyramidal disorders studied here may reflect the fact that the drug is a partial D-l receptor agonist.'5 Conceivably, SKF 38393 may produce clinically significant effects only at doses above or below those used in the present study. Nevertheless, at least in the case of Huntington's disease, this seems unlikely since motor function was formally assessed over a broad dose range without apparent effect. Alternatively, despite its high selectively in vitro and its behavioural potency in laboratory animals, SKF 38393 may not have identical pharmacologic properties in man. If this is true, acute administration of this agent may not actually reflect the effect of D-I receptor stimulation in hyperkinetic extrapyramidal disease.
Other explanations are also possible. Pathological changes in Huntington's disease involve degeneration of medium spiny neurons projecting from the striatum to primary outflow regions such as globus pallidus and substantia nigra reticulata.'6 The highest cerebral concentrations of D-1 receptors are found in these regions, located presynaptically on terminals of the medium spiny afferents." The number of these receptors may thus be substantially reduced in Huntington's disease, and D-1 receptors could therefore be involved in the pathophysiology of this disorder by virtue of their absence. Consequently, SKF 38393 would have no effect on motor or cognitive signs. Such pathological changes appear to be unique to Huntington's disease, however, and would not readily explain Finally, D-l dopamine receptors might contribute to the pathophysiology of these disorders by virtue of their interaction with D-2 receptors, a possibility which is not directly addressed in the present study. Preclinical investigations have documented a complex functional interaction between D-1 and D-2 receptors and suggested that the D-1 receptor may exert its most profound effects only when the D-2 receptor is concurrently stimulated."'9 Indeed, some studies suggest that such an interaction may be essential.7 Clinical observations support this possibility; SKF 38393 administered alone has no apparent effect on motor function in Parkinson's disease, but may modify dyskinesias induced by levodopa.'2 If a functional interaction between receptor subtypes plays a role in the pathogenesis of motor or cognitive phenomena associated with hyperkinetic extrapyramidal disease, it will necessarily be documented only by further studies utilising combinations of selective D-1 and D-2 receptor agonists or antagonists.
In summary, our results suggest that the subacute administration ofthe D-l receptor agonist SKF 38393 has no clinically significant effect on motor or cognitive function in patients with various hyperkinetic extrapyramidal disorders. While these negative results may be due to methodological limitations, they might also suggest the D-1 receptor mediated mechanisms do not contribute significantly to the pathophysiology of these diseases. On the other hand, the D-1 receptor may in fact play a substantial role in the pathogenesis of hyperkinetic extrapyramidal disorders which cannot be adequately characterised by the administration of SKF 38393.
